Abstract 429P
Background
The impact of COVID-19 has been concerning in management of the non-COVID diseases, especially cancer. We conducted an online survey to study the impact COVID-19 had on cancer-related care.
Methods
The survey was conducted in collaboration with OncoAlert between March 2022 and June 2022 through google forms which were mainly circulated through the ONCOassist app and other social platforms including emails to various oncology-related specialties.
Results
The online questionnaire was completed by 155 respondents and the majority were males (71%) who were relatively young (85.1% were in the age group 25-45 years). The majority were radiation oncologists (52.3%) and Medical Oncologists (29%). About 3/4th of the centers admitted admit COVID patients in their centers and 81.3% believed cancer care was hampered due to the pandemic. About 79.4% provided telemedicine facilities and 18.8% conveyed that more than 25% of cancer patients were managed by this facility. COVID testing was done before starting therapy with 65.4%, 54.9%, and 52.3% sharing the need for the test prior to surgery, chemotherapy, or the start of radiation therapy respectively. Only 11.1% felt the need to deviate from the standard of care more than 50% of the time. The majority (74.5%) felt there was a delay in diagnosis and 81.7% and 80.4% felt there was progression to advanced stages or patients were lost to follow-up respectively. About 56.9% felt that they provided substandard treatment to their patients. Education and training in oncology too took a hit during the pandemic as examinations for the specialties in oncology needed to be conducted on the online platform (46%). About 22.9%, 10.8%, and 14.2% felt that more than 50% of surgeries, chemotherapy, and radiation treatment needed to be canceled. Unfortunately, 21.8% reported having to make changes in the curative intent of treatment. The recruitment delays and halts (87.5%) were major factors that impacted the oncology-related research and 52.8% did not start new research. About 59.3% have used the Oncoassist mobile application for more than a year.
Conclusions
Decision-making in oncology has been influenced by the COVID-19 pandemic. Telehealth is a novel concept that is being encouraged and used by clinicians to improve patient care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B. Devnani: Financial Interests, Personal, Invited Speaker, Invited for a lecture in Sabah Rectal cancer summit and recieved 300 dollars for the same: Sabah Rectal Cancer Society, Malaysia; Financial Interests, Personal, Officer, I am chairperson of committee for making Consensus document for management of Melanoma and CNS tumors and member of Survivorship committee: Indian Council of Medical Research; Non-Financial Interests, Personal, Leadership Role, Facebook editor of Oncoalert network: Oncoalert; Non-Financial Interests, Personal, Member, Life time member: Association of Radiation Oncologists of India, Indian Society of Neuro-Oncology; Non-Financial Interests, Personal, Member, Member in 2019-2020: ASTRO; Non-Financial Interests, Personal, Member, Member of Society: Indian Society of Oncology. K.D. Bambury: Financial Interests, Institutional, Invited Speaker, I am a director and full-time employee of ONCOassist. ONCOassist receives sponsorship from various pharmaceutical companies.: ONCOassist; Financial Interests, Personal, Ownership Interest: ONCOassist. G. Morgan: Financial Interests, Personal, Advisory Board, Advisory board: Pfizer, Roche; Financial Interests, Personal, Invited Speaker, Invited lecturer: Novartis; Financial Interests, Personal, Invited Speaker, invited speaker: Astra Zeneca; Non-Financial Interests, Personal, Advisory Role, Advisory Board eESO: ESO; Non-Financial Interests, Personal, Leadership Role, Director of OncoAlert Network: OncoAlert. All other authors have declared no conflicts of interest.
Resources from the same session
451P - The activity and safety of anlotinib combined with chemotherapy for patients with desmoid tumor: A retrospective study in a single institution
Presenter: Peng Zhang
Session: Poster viewing 06
452P - Medical and paramedical students’ awareness of environmental risk factors for cancer
Presenter: Mostafa Behery
Session: Poster viewing 06
453P - Relationship between Interleukin-6 Levels (IL-6) and COVID-19 vaccination status in cancer patients at Dr. Moewardi General Hospital, Indonesia
Presenter: Rico Hutabarat
Session: Poster viewing 06
454P - To study the prevalence of lower limb deep vein thrombosis in patients who present with stage III/IV solid tissue malignancies in Indian patients
Presenter: Oshin Suri
Session: Poster viewing 06
455P - Succinate dehydrogenase deficient GIST: Case series and review of literature from a tertiary care centre in India
Presenter: Akhil Santhosh
Session: Poster viewing 06
456P - Outcomes of COVID-19 infection in cancer patients: A single center study
Presenter: Sindhu G
Session: Poster viewing 06
457P - The effect of Interleukin-6 (IL-6) on malignancy in COVID-19 patients in Dr. Moewardi General Hospital Surakarta
Presenter: Meirisa Ardianti
Session: Poster viewing 06
458P - A real-world depiction of difficulties in applicability of IO regimens into clinical practice in metastatic setting
Presenter: Sharat Chandra Goteti
Session: Poster viewing 06
460P - The role of fluorescence-based cell-free DNA assay for detection of cancer by comparing patients with and without cancer
Presenter: Jae-Joon Kim
Session: Poster viewing 06
461P - Spectrum of immune related adverse events (irAE) on treatment with checkpoint inhibitors and its association with survival: A real-world experience from India
Presenter: Nitin Murthy
Session: Poster viewing 06